Mineralized and GSH-responsive hyaluronic acid based nano-carriers for potentiating repressive effects of sulforaphane on breast cancer stem cells-like properties

Gu, Haofeng; Ren, Fazheng; Mao, Xueying; Du, Min

doi:10.1016/j.carbpol.2021.118294

Cited by 25 publications

(21 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, SFN/M-HA-SS-TA exhibited better suppression of BCSC in vitro and in vivo compared to free SFN. Overall, M-HA-SS-TA provides a new strategy for both the preparation of amphiphilic nanoparticles and the treatment of breast cancer ( Gu et al, 2021 ).…”

Section: Modified Ha Nddssmentioning

confidence: 99%

Hyaluronic acid-based nano drug delivery systems for breast cancer treatment: Recent advances

Jia

Chen

Wang

et al. 2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Breast cancer (BC) is the most common malignancy among females worldwide, and high resistance to drugs and metastasis rates are the leading causes of death in BC patients. Releasing anti-cancer drugs precisely to the tumor site can improve the efficacy and reduce the side effects on the body. Natural polymers are attracting extensive interest as drug carriers in treating breast cancer. Hyaluronic acid (HA) is a natural polysaccharide with excellent biocompatibility, biodegradability, and non-immunogenicity and is a significant component of the extracellular matrix. The CD44 receptor of HA is overexpressed in breast cancer cells and can be targeted to breast tumors. Therefore, many researchers have developed nano drug delivery systems (NDDS) based on the CD44 receptor tumor-targeting properties of HA. This review examines the application of HA in NDDSs for breast cancer in recent years. Based on the structural composition of NDDSs, they are divided into HA NDDSs, Modified HA NDDSs, and HA hybrid NDDSs.

show abstract

Section: Modified Ha Nddssmentioning

confidence: 99%

Hyaluronic acid-based nano drug delivery systems for breast cancer treatment: Recent advances

Jia

Chen

Wang

et al. 2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

show abstract

“…179 Gu et al developed mineralized hyaluronic acid-SS-tetradecyl nanocarriers that are responsive to highly reducing and mildly acidic tumor microenvironments, and could rapidly deliver SFN and target CD44+ breast CSCs via HA, enhancing the efficacy of SFN in inhibiting CSCs-like properties and significantly inhibit CSCs invasion, self-renewal and tumor growth. 180 Likewise, by targeting the Wnt/β-catenin signaling pathway, the SFN-loaded nanoparticles significantly inhibited the self-renewal of breast CSCs and improved their chemotherapy sensitivity, and its combination with doxorubicin can eliminate both cancer cells and CSCs, thus effectively eradicating breast cancer. 181 International Journal of Nanomedicine 2022:17 https://doi.org/10.2147/IJN.S380697…”

Section: Alkaloidsmentioning

confidence: 99%

Natural Products-Based Nanoformulations: A New Approach Targeting CSCs to Cancer Therapy

Liao¹,

Li²,

Wang

et al. 2022

IJN

View full text Add to dashboard Cite

Cancer stem cells (CSCs) lead to the occurrence and progression of cancer due to their strong tumorigenic, self-renewal, and multidirectional differentiation abilities. Existing cancer treatment methods cannot effectively kill or inhibit CSCs but instead enrich them and produce stronger proliferation, invasion, and metastasis capabilities, resulting in cancer recurrence and treatment resistance, which has become a difficult problem in clinical treatment. Therefore, targeting CSCs may be the most promising approach for comprehensive cancer therapy in the future. A variety of natural products (NP) have significant antitumor effects and have been identified to target and inhibit CSCs. However, pharmacokinetic defects and off-target effects have greatly hindered their clinical translation. NP-based nanoformulations (NPNs) have tremendous potential to overcome the disadvantages of NP against CSCs through site-specific delivery and by improving their pharmacokinetic parameters. In this review, we summarize the recent progress of NPNs targeting CSCs in cancer therapy, looking forward to transforming preclinical research results into clinical applications and bringing new prospects for cancer treatment.

show abstract

“…In vivo analyses showed the rapid accumulation and sulforaphane release in situ after 6 h, the localization increased after 24 h post injection. Furthermore, the sulforaphane concentration was higher at the excised tumour in comparison with other organs, demonstrating CD44 targeting specificity and a low toxicity system [ 76 ].…”

Section: Anti-tumour Effects Of Sulforaphane Nanoparticles: Promising...mentioning

confidence: 99%

Molecular Pathways Related to Sulforaphane as Adjuvant Treatment: A Nanomedicine Perspective in Breast Cancer

et al. 2022

View full text Add to dashboard Cite

Because cancer is a multifactorial disease, it is difficult to identify the specific agents responsible for the disease’s progression and development, but lifestyle and diet have been shown to play a significant role. Diverse natural compounds are demonstrating efficacy in the development of novel cancer therapies, including sulforaphane (1-isothiocyanate-4-(methylsulfinyl)butane), a compound found in broccoli and other cruciferous vegetables that promotes key biological processes such as apoptosis, cell cycle arrest, autophagy, and suppression of key signalling pathways such as the PI3K/AKT/mTOR pathway in breast cancer cells. However, one of the primary challenges with sulforaphane treatment is its low solubility in water and oral bioavailability. As a consequence, several investigations were conducted using this component complexed in nanoparticles, which resulted in superior outcomes when combined with chemotherapy drugs. In this study, we discuss the properties and benefits of sulforaphane in cancer therapy, as well as its ability to form complexes with nanomolecules and chemotherapeutic agents that synergize the antitumour response in breast cancer cells.

show abstract

Mineralized and GSH-responsive hyaluronic acid based nano-carriers for potentiating repressive effects of sulforaphane on breast cancer stem cells-like properties

Cited by 25 publications

References 38 publications

Hyaluronic acid-based nano drug delivery systems for breast cancer treatment: Recent advances

Hyaluronic acid-based nano drug delivery systems for breast cancer treatment: Recent advances

Natural Products-Based Nanoformulations: A New Approach Targeting CSCs to Cancer Therapy

Molecular Pathways Related to Sulforaphane as Adjuvant Treatment: A Nanomedicine Perspective in Breast Cancer

Contact Info

Product

Resources

About